\documentclass[11pt,twoside]{article}\makeatletter

\IfFileExists{xcolor.sty}%
  {\RequirePackage{xcolor}}%
  {\RequirePackage{color}}
\usepackage{colortbl}
\usepackage{wrapfig}
\usepackage{ifxetex}
\ifxetex
  \usepackage{fontspec}
  \usepackage{xunicode}
  \catcode`⃥=\active \def⃥{\textbackslash}
  \catcode`❴=\active \def❴{\{}
  \catcode`❵=\active \def❵{\}}
  \def\textJapanese{\fontspec{Noto Sans CJK JP}}
  \def\textChinese{\fontspec{Noto Sans CJK SC}}
  \def\textKorean{\fontspec{Noto Sans CJK KR}}
  \setmonofont{DejaVu Sans Mono}
  
\else
  \IfFileExists{utf8x.def}%
   {\usepackage[utf8x]{inputenc}
      \PrerenderUnicode{–}
    }%
   {\usepackage[utf8]{inputenc}}
  \usepackage[english]{babel}
  \usepackage[T1]{fontenc}
  \usepackage{float}
  \usepackage[]{ucs}
  \uc@dclc{8421}{default}{\textbackslash }
  \uc@dclc{10100}{default}{\{}
  \uc@dclc{10101}{default}{\}}
  \uc@dclc{8491}{default}{\AA{}}
  \uc@dclc{8239}{default}{\,}
  \uc@dclc{20154}{default}{ }
  \uc@dclc{10148}{default}{>}
  \def\textschwa{\rotatebox{-90}{e}}
  \def\textJapanese{}
  \def\textChinese{}
  \IfFileExists{tipa.sty}{\usepackage{tipa}}{}
\fi
\def\exampleFont{\ttfamily\small}
\DeclareTextSymbol{\textpi}{OML}{25}
\usepackage{relsize}
\RequirePackage{array}
\def\@testpach{\@chclass
 \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else
  \ifnum \@lastchclass=7 5 \else
   \ifnum \@lastchclass=8 \tw@ \else
    \ifnum \@lastchclass=9 \thr@@
   \else \z@
   \ifnum \@lastchclass = 10 \else
   \edef\@nextchar{\expandafter\string\@nextchar}%
   \@chnum
   \if \@nextchar c\z@ \else
    \if \@nextchar l\@ne \else
     \if \@nextchar r\tw@ \else
   \z@ \@chclass
   \if\@nextchar |\@ne \else
    \if \@nextchar !6 \else
     \if \@nextchar @7 \else
      \if \@nextchar (8 \else
       \if \@nextchar )9 \else
  10
  \@chnum
  \if \@nextchar m\thr@@\else
   \if \@nextchar p4 \else
    \if \@nextchar b5 \else
   \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi
   \fi \fi  \fi  \fi  \fi  \fi  \fi \fi \fi \fi \fi \fi}
\gdef\arraybackslash{\let\\=\@arraycr}
\def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}}
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\def\abbr{}
\def\corr{}
\def\expan{}
\def\gap{}
\def\orig{}
\def\reg{}
\def\ref{}
\def\sic{}
\def\persName{}\def\name{}
\def\placeName{}
\def\orgName{}
\def\textcal#1{{\fontspec{Lucida Calligraphy}#1}}
\def\textgothic#1{{\fontspec{Lucida Blackletter}#1}}
\def\textlarge#1{{\large #1}}
\def\textoverbar#1{\ensuremath{\overline{#1}}}
\def\textquoted#1{‘#1’}
\def\textsmall#1{{\small #1}}
\def\textsubscript#1{\@textsubscript{\selectfont#1}}
\def\textxi{\ensuremath{\xi}}
\def\titlem{\itshape}
\newenvironment{biblfree}{}{\ifvmode\par\fi }
\newenvironment{bibl}{}{}
\newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par }
\newenvironment{citbibl}{}{\ifvmode\par\fi }
\newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi }
\newenvironment{docDate}{}{\ifvmode\par\fi }
\newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi }
\newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par }
\newenvironment{msHead}{\vskip 6pt}{\par}
\newenvironment{msItem}{\vskip 6pt}{\par}
\newenvironment{rubric}{}{}
\newenvironment{titlePart}{}{\par }

\newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}}
\newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}}
\newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}}
\newcolumntype{P}[1]{){\arraybackslash}p{#1}}
\newcolumntype{B}[1]{){\arraybackslash}b{#1}}
\newcolumntype{M}[1]{){\arraybackslash}m{#1}}
\definecolor{label}{gray}{0.75}
\def\unusedattribute#1{\sout{\textcolor{label}{#1}}}
\DeclareRobustCommand*{\xref}{\hyper@normalise\xref@}
\def\xref@#1#2{\hyper@linkurl{#2}{#1}}
\begingroup
\catcode`\_=\active
\gdef_#1{\ensuremath{\sb{\mathrm{#1}}}}
\endgroup
\mathcode`\_=\string"8000
\catcode`\_=12\relax

\usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry}
\usepackage{framed}

\definecolor{shadecolor}{gray}{0.95}
\usepackage{longtable}
\usepackage[normalem]{ulem}
\usepackage{fancyvrb}
\usepackage{fancyhdr}
\usepackage{graphicx}
\usepackage{marginnote}

\renewcommand{\@cite}[1]{#1}


\renewcommand*{\marginfont}{\itshape\footnotesize}

\def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif}

  \pagestyle{fancy}

\usepackage[pdftitle={Pharmacovigilance Programme of India: A Review},
 pdfauthor={}]{hyperref}
\hyperbaseurl{}

	 \paperwidth210mm
	 \paperheight297mm
              
\def\@pnumwidth{1.55em}
\def\@tocrmarg {2.55em}
\def\@dotsep{4.5}
\setcounter{tocdepth}{3}
\clubpenalty=8000
\emergencystretch 3em
\hbadness=4000
\hyphenpenalty=400
\pretolerance=750
\tolerance=2000
\vbadness=4000
\widowpenalty=10000

\renewcommand\section{\@startsection {section}{1}{\z@}%
     {-1.75ex \@plus -0.5ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large\bfseries}}
\renewcommand\subsection{\@startsection{subsection}{2}{\z@}%
     {-1.75ex\@plus -0.5ex \@minus- .2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large}}
\renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}%
     {-1.5ex\@plus -0.35ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\large}}
\renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}%
     {-1ex \@plus-0.35ex \@minus -0.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\normalsize}}
\renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}%
     {1.5ex \@plus1ex \@minus .2ex}%
     {-1em}%
     {\reset@font\normalsize\bfseries}}


\def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt}
 \@tempdima 1.5em \begingroup
 \parindent \z@ \rightskip \@pnumwidth 
 \parfillskip -\@pnumwidth 
 \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par
 \endgroup}
\def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}}
\def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}}
\def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}}
\def\l@subparagraph{\@dottedtocline{5}{10em}{5em}}
\@ifundefined{c@section}{\newcounter{section}}{}
\@ifundefined{c@chapter}{\newcounter{chapter}}{}
\newif\if@mainmatter 
\@mainmattertrue
\def\chaptername{Chapter}
\def\frontmatter{%
  \pagenumbering{roman}
  \def\thechapter{\@roman\c@chapter}
  \def\theHchapter{\roman{chapter}}
  \def\thesection{\@roman\c@section}
  \def\theHsection{\roman{section}}
  \def\@chapapp{}%
}
\def\mainmatter{%
  \cleardoublepage
  \def\thechapter{\@arabic\c@chapter}
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \pagenumbering{arabic}
  \setcounter{secnumdepth}{6}
  \def\@chapapp{\chaptername}%
  \def\theHchapter{\arabic{chapter}}
  \def\thesection{\@arabic\c@section}
  \def\theHsection{\arabic{section}}
}
\def\backmatter{%
  \cleardoublepage
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \setcounter{secnumdepth}{2}
  \def\@chapapp{\appendixname}%
  \def\thechapter{\@Alph\c@chapter}
  \def\theHchapter{\Alph{chapter}}
  \appendix
}
\newenvironment{bibitemlist}[1]{%
   \list{\@biblabel{\@arabic\c@enumiv}}%
       {\settowidth\labelwidth{\@biblabel{#1}}%
        \leftmargin\labelwidth
        \advance\leftmargin\labelsep
        \@openbib@code
        \usecounter{enumiv}%
        \let\p@enumiv\@empty
        \renewcommand\theenumiv{\@arabic\c@enumiv}%
	}%
  \sloppy
  \clubpenalty4000
  \@clubpenalty \clubpenalty
  \widowpenalty4000%
  \sfcode`\.\@m}%
  {\def\@noitemerr
    {\@latex@warning{Empty `bibitemlist' environment}}%
    \endlist}

\def\tableofcontents{\section*{\contentsname}\@starttoc{toc}}
\parskip0pt
\parindent1em
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\newenvironment{reflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemsep}{0pt}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\itshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{sansreflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\itemsep}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\upshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{specHead}[2]%
 {\vspace{20pt}\hrule\vspace{10pt}%
  \phantomsection\label{#1}\markright{#2}%

  \pdfbookmark[2]{#2}{#1}%
  \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}%
  }{}
      \def\TheFullDate{2019-01-15 (revised: 15 January 2019)}
\def\TheID{\makeatother }
\def\TheDate{2019-01-15}
\title{Pharmacovigilance Programme of India: A Review}
\author{}\makeatletter 
\makeatletter
\newcommand*{\cleartoleftpage}{%
  \clearpage
    \if@twoside
    \ifodd\c@page
      \hbox{}\newpage
      \if@twocolumn
        \hbox{}\newpage
      \fi
    \fi
  \fi
}
\makeatother
\makeatletter
\thispagestyle{empty}
\markright{\@title}\markboth{\@title}{\@author}
\renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@
\belowdisplayskip \abovedisplayskip
\abovedisplayshortskip \z@ plus2\p@
\belowdisplayshortskip 4\p@ plus2\p@ minus2\p@
\def\@listi{\leftmargin\leftmargini
               \topsep 2\p@ plus1\p@ minus1\p@
               \parsep 2\p@ plus\p@ minus\p@
               \itemsep 1pt}
}
\makeatother
\fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm}
\fancyhf{} 
\setlength{\headheight}{14pt}
\fancyhead[LE]{\bfseries\leftmark} 
\fancyhead[RO]{\bfseries\rightmark} 
\fancyfoot[RO]{}
\fancyfoot[CO]{\thepage}
\fancyfoot[LO]{\TheID}
\fancyfoot[LE]{}
\fancyfoot[CE]{\thepage}
\fancyfoot[RE]{\TheID}
\hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true}
\fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}}

\date{}
\usepackage{authblk}

\providecommand{\keywords}[1]
{
\footnotesize
  \textbf{\textit{Index terms---}} #1
}

\usepackage{graphicx,xcolor}
\definecolor{GJBlue}{HTML}{273B81}
\definecolor{GJLightBlue}{HTML}{0A9DD9}
\definecolor{GJMediumGrey}{HTML}{6D6E70}
\definecolor{GJLightGrey}{HTML}{929497} 

\renewenvironment{abstract}{%
   \setlength{\parindent}{0pt}\raggedright
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
   \textcolor{GJBlue}{\large\bfseries\abstractname\space}
}{%   
   \vskip8pt
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
}

\usepackage[absolute,overlay]{textpos}

\makeatother 
      \usepackage{lineno}
      \linenumbers
      
\begin{document}

             \author[1]{Saurabh  Nimesh}

             \author[2]{Surabhi  Gupta}

             \author[3]{Kapil Dev  Negi}

             \affil[1]{  Meerut Institute of Engineering and Technology}

\renewcommand\Authands{ and }

\date{\small \em Received: 10 December 2018 Accepted: 4 January 2019 Published: 15 January 2019}

\maketitle


\begin{abstract}
        


Background: In India, a proper adverse drug reaction monitoring system was started in 1986 with 12 regional centers. In 1997, India became the member of the World health organization Programme for International Drug watching managed by the Upsala Monitoring Centre, Sweden. At origination, 6 regional centers were created in Mumbai, New Delhi, Kolkata, Lucknow, Pondicherry, and Chandigarh for ADR watching within the country. Promoting safe use of drugs may be a priority of the Indian Pharmacopoeia Commission that functions as the National Coordination Centre for Pharmacovigilance Programme of India. Today, 179 adverse drug reactions monitoring centers presently report adverse events to the National coordinative centre in India.

\end{abstract}


\keywords{vigiflow, UMC, death, thalidomide, reporting form, phocomelia.}

\begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) 
\textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark}
\end{textblock*}

\begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) 
\textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}}
\end{textblock*}


\let\tabcellsep& 	 	 		 
\section[{Introduction}]{Introduction}\par
ccording to World Health Organisation (WHO), Pharmacovigilance (PV) as the pharmacological science and activities relating to the monitoring, detection, assessment, understanding, and prevention of adverse drug reactions (ADRs), or any long-term and short-term medicine-related problems (Figure \hyperref[fig_1]{1\&2}). Variety of ADRs associated with medication prompted the event of the science of PV \hyperref[b0]{[1]}\hyperref[b1]{[2]}\hyperref[b2]{[3]} {\ref [4]} . This prompted WHO for a systematic study of ADR of medicine, that is that the starting of PV. Thenceforth variety of ADRs was detected, a number of that square measure shows in (Table \hyperref[tab_0]{1}). ADR is taken into account to be the 6 th leading reason behind death. India, with a current population of 1.27 billion, is that the 4th largest producers of prescription drugs within the world with quite 6000 licensed makers and over 60000 branded formulations within the market. In the United States of America, ADRs contribute 3-7\% of hospital admissions. In England, 1\% chronicles of the entire hospital admissions were due to ADRs throughout the year 1999-2008. ADRs square measure common in the Australian healthcare system additionally and that they contribute to a 1\% of hospital admissions \hyperref[b3]{[5,}\hyperref[b4]{6]} . The percentage of hospital admissions due to ADRs in bound countries is 100\% or additional.\par
Drug attributed deaths square measure calculable to be 0.19\% altogether medical inpatients. About 0.40\% of ADRs known were directly joined to high costs. ADRs not solely increase the mortality and morbidity; however, additionally multiply the health care value \hyperref[b5]{[7]} . The PV effort within India is coordinated bythe Indian Pharmacopoeia Commission (IPC) and conducted by the Central Drugs Standard Control Organization (CDSCO). The most responsibility of the IPC is to keep up and develop the PV database consisting of all suspected ADR to medicines observed. IPC is functioning as a National Coordination Centre (NCC) for the Pharmacovigilance Programme of India (PvPI). NCC is working underneath the direction of a committee that recommends procedures and guidelines for regulatory interventions \hyperref[b6]{[8]} .The main responsibility of NCC is to watch all the ADR of medicines being observed within the Indian population and to develop and maintain its PV information. The aim of the commission that acts just like the NCC for PvPI is for the safety of the patient, and the population with relevancy use of the drug. The Commission has become operational from 1 st January 2009 an associate autonomous body, absolutely supported by the central government with specific fund allocations under the administrative control of the Ministry of Health and Family Welfare \hyperref[b7]{[9]} . The Secretary, Ministry of Health and Family Welfare, is the Chairperson and therefore the Chairman-Scientific Body is that the Co-Chairman of the Commission. The Secretary-cum Scientific Director is that the Chief Scientific and Executive officer of the Commission. The CDSCO, Directorate General of Health Services underneath the aegis of Ministry of Health \& Family Welfare, Government of India unitedly with IPC, Ghaziabad is initiating a nation-wide PV program for shielding the health of the patients by reassuring drug safety. The program shall be coordinated by the IPC, as an NCC. The center can operate underneath the superintendence of a steering committee. The PvPI was initiated by the government of India on 14 th July 2010 with the All India Institute of Medical Sciences (AIIMS), New Delhi as the NCC for monitoring ADRs in the country for safeguarding public health. Within the year 2010, 22 ADR monitoring center, as well as AIIMS, came upon underneath this program  {\ref [10]}\hyperref[b8]{[11]}\hyperref[b9]{[12]}\hyperref[b11]{[13]} . To confirm the implementation of this program in an exceedingly method, the NCC was shifted from the AIIMS to the IPC, Ghaziabad, Uttar Pradesh on 15th April 2011 (Figure \hyperref[fig_2]{3}).    The concept of PV is not new, because the time of Charak Samhita in 700 BC had cautioned that properly understood however improperly administered drug is Vagueness poison and Vagbhatta-a physician represented adverse events, reason, delayed ADRs to Ayurvedic Drugs' around 500 AD. After that, many reports of ADRs from India area unit found within the history of modern medicine, but there was no systematic effort of ADR monitoring since the primary try was created in 1989 \hyperref[b13]{[15,}\hyperref[b14]{16]} . 
\section[{III. Scope of the Pharmacovigilance Programme of India}]{III. Scope of the Pharmacovigilance Programme of India}\par
Before registration and selling of drugs within the country, its safety and efficaciousness expertise area unit primarily based totally on the employment of the drugs in clinical trials. These trials in the notice common ADR. Some vital reactions, like those, that take a protracted time to develop, or those, that occur seldom, might not be detected in clinical trials. Additionally, the controlled conditions beneath that medicines area unit utilized in clinical trials don't essentially replicate the method they will be utilized in observe. For a drug to be thought-about safe, its expected advantages ought to be more than any associated risks of harmful reactions. So, to achieve a comprehensive safety profile of drugs, a continuous post-marketing monitoring system, i.e. PV is crucial. To monitor the security of drugs, information from several sources is employed for PV \hyperref[b15]{[17]} . These embrace spontaneous ADRs coverage mechanism; medical literature published worldwide; action taken by regulative authorities in alternative countries. Since there exist substantial social and economic consequences of ADRs and therefore the positive benefit/cost magnitude relation of implementing applicable risk management -there may be a have to be compelled to interact health care professionals and therefore the public at massive, during a well-structured program to make synergies for watching ADRs within the country. The PvPI aims is to collate data, method and analyze it and use the inferences to advocate regulative interventions, besides human action risks to health care professionals and therefore, the public \hyperref[b16]{[18 ]}.\par
IV. 
\section[{Management of the Pharmacovigilance Programme of India}]{Management of the Pharmacovigilance Programme of India}\par
This is headed by the Secretary cum scientific Director: Dr. Gyanendra Nath Singh, who is working with the help of Advisor and National Scientific Coordinator supported by the several committees like-Steering Committee, Working Group, Quality Review Panel, Core Training Panel, etc. involving experts from all over the country.Current Status of NCC-PvPI Presently the PvPI program has more than 200 Adverse Drug Monitoring Centres (AMCs) involving all states and Union Territories through-out India \hyperref[b17]{[19]} .\par
V. 
\section[{Reporting of Adverse Drug Reactions}]{Reporting of Adverse Drug Reactions}\par
Suspected ADR reporting forms for health care professionals (Figure  {\ref 4}) and consumers (Figure  {\ref 5}) a unit available on the website of IPC to report ADR. To get rid of barrier in ADR reporting, the consumer reporting form is available in 10 vernacular languages (Hindi, Tamil, Telugu, Kannada, Bengali, Gujarati, Assamese, Marathi, Oriya, and Malayalam). ADRs will be conjointly reportable via PvPI helpline number (18001803024) on week days from 9:00 am to 5:30 pm. The mobile Android application for ADR reporting has conjointly been created available to the general public \hyperref[b18]{[20]} . 
\section[{VI.}]{VI.} 
\section[{World Health Organization-Uppsala Monitoring Centre \& India}]{World Health Organization-Uppsala Monitoring Centre \& India}\par
The WHO Program for International Drug Monitoring provides a forum for WHO member states that has India to collaborate within the monitoring of drug safety. At intervals the Program, individual case reports of suspected ADRs are collected and keep in an exceedingly common information, presently containing over 3.7 million case reports. Since 1978, the Uppsala Monitoring Centre (UMC) in Sweden has dispensed the Program. The UMC is accountable for the gathering of knowledge concerning ADRs from around the world, particularly from countries that are members of the WHO together with India. Member countries send their reports to the UMC wherever they are processed, evaluated, and entered into the WHO International information. When there are several reports of adverse reactions to a particular drug, this process may lead to the detection of a signal-an alert about a possible hazard communicated to member countries. This happens solely once elaborated analysis and expert review. These ADR reports are assessed regionally and will cause the action at intervals in the country. Through membership of the WHO International Drug Monitoring Program, a rustic will recognize if similar reports are being created elsewhere. India is a country with a large patient pool and healthcare professionals, yet ADR reporting is in its infancy (Table \hyperref[tab_1]{2}) \hyperref[b19]{[21]}\hyperref[b20]{[22]}\hyperref[b21]{[23]} .  
\section[{VII.}]{VII.} 
\section[{Aim of the Pharmacovigilance Programme of India}]{Aim of the Pharmacovigilance Programme of India}\par
Pharmacovigilance has specific aims as follows:\par
1. Improve patient care and safety in about the use of medicines and all medical and paramedical interventions. 2. Improve public health and safety in about the use of medicines. 3. Contribute to the assessment of benefit, harm, effectiveness, and risk of medicines, encouraging their safe, rational and more effective (including cost-effective) use. 
\section[{Promote understanding, education, and clinical}]{Promote understanding, education, and clinical}\par
training in PV and its effective communication to the public \hyperref[b22]{[24]} . IX. 
\section[{Conclusion}]{Conclusion}\par
The adverse drug reaction observation and reporting programs or pharmacovigilance program of India is aiming to identify the risks related to the utilization of the drugs. The current analysis has disclosed opportunities or interventions particularly or avertible adverse events, which arecan to facilitate in promoting safer drug use, data to the health care professionals. Improve the standard of patient care and educate to extend awareness. Therefore, currently, this point has returned to aware the general public too for the reporting the adverse drug reaction to the nearest hospital or ADR monitoring center or the health care professionals. They will directly report the adverse drug reaction through the government. Toll-free number 18001803024, adverse drug reaction application, email, and alternative methodology like social media.  
\section[{B}]{B}\par
Pharmacovigilance Programme of India: A Review 4. To generate the evidence-based information on the safety of medicines. 5. To support regulatory agencies in the decisionmaking process on the use of medications. 6. To communicate the safety information on the use of medicines to various stakeholders to minimize the risk. 7. To emerge as a national center of excellence for PV activities. 8. To collaborate with other national centers for the exchange of information and data management. 9. To provide training and consultancy support to other national PV centers located across the globe \hyperref[b23]{[25,}\hyperref[b24]{26]} .\begin{figure}[htbp]
\noindent\textbf{1}\includegraphics[]{image-2.png}
\caption{\label{fig_0}Figure 1 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{2}\includegraphics[]{image-3.png}
\caption{\label{fig_1}Figure 2 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{3}\includegraphics[]{image-4.png}
\caption{\label{fig_2}Figure 3 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{1} \par 
\begin{longtable}{P{0.24367945823927764\textwidth}P{0.007674943566591421\textwidth}P{0.07674943566591422\textwidth}P{0.5218961625282167\textwidth}}
Sr. No.\tabcellsep Drug\tabcellsep Year\tabcellsep Serious \& unexpected adverse event\\
\multicolumn{2}{l}{Chloroform (Anaesthetic)}\tabcellsep 1848\tabcellsep Episode of ventricular fibrillation \& death\\
\multicolumn{2}{l}{Sulphanilamide (Elixir)}\tabcellsep 1937\tabcellsep Death\\
\multicolumn{2}{l}{Thalidomide}\tabcellsep 1961\tabcellsep Amelia, phocomelia \&dysmelia\\
\multicolumn{2}{l}{Clioquinol}\tabcellsep 1970\tabcellsep Subacute nephropathy\\
Practolol\tabcellsep \tabcellsep 1975\tabcellsep Sclerosing peritonitis\\
\multicolumn{2}{l}{Benoxaprofen}\tabcellsep 1982\tabcellsep Nephrotoxicity\&cholestatic jaundice\\
\multicolumn{2}{l}{Terfenadine}\tabcellsep 1997\tabcellsep Torsade de pointes\\
\multicolumn{2}{l}{Rofecoxib}\tabcellsep 2004\tabcellsep Cardiovascular effects\\
\multicolumn{2}{l}{Veralipride}\tabcellsep 2007\tabcellsep Anxiety, depression \& movement disorders\end{longtable} \par
 
\caption{\label{tab_0}Table 1 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{2} \par 
\begin{longtable}{P{0.2106245756958588\textwidth}P{0.6393754243041412\textwidth}}
Centre\tabcellsep Role\\
\tabcellsep Collection of ADR reports, perform follow up with the\\
\tabcellsep complainant to check completeness as per standard\\
\tabcellsep operating procedure (SOPs), data entry into Vigiflow,\\
ADR monitoring centre\tabcellsep reporting to PvPI-NCC through Vigiflow with the source\\
\tabcellsep data (original) attached with each ADR caseTraining/\\
\tabcellsep sensitization/ feedback to physicians through newsletters\\
\tabcellsep circulated by the PvPI-NCC.\\
PvPI AMC other than medical colleges [Corporate\tabcellsep \\
hospitals, autonomous institutes, Pharmaceutical\tabcellsep \\
industry and public health Programmers]\tabcellsep \\
\tabcellsep Preparation of SOPs, guidance documents \& training\\
\tabcellsep manuals,\\
Pharmacovigilance programme of India, National\tabcellsep data collation, Cross-check completeness, Causality\\
coordinating centre, Indian pharmacopoeia\tabcellsep Assessment etc as per SOPs, conduct Training\\
commission(Ghaziabad)\tabcellsep workshops of all enrolled centres, publication of\\
\tabcellsep medicines safety newsletter, reporting to CDSCO-HQ,\\
\tabcellsep Analysis of the Performance measurement system,\\
\tabcellsep Periodic safety update report, Adverse event following\\
\tabcellsep immunization data received from CDSCO-HQ.\\
\tabcellsep Provide procurement, financial and administrative support\\
Zonal/Sub-zonal CDSCO Offices\tabcellsep to ADR monitoring centres, report to CDSCO-HQ.\\
\tabcellsep Take appropriate regulatory decision \& actions on the\\
\tabcellsep basis of recommendations of PvPI NCC at IPC,\\
Central drugs standard control organization-\tabcellsep propagation of medicine safety related decisions to\\
Headquarter (New Delhi)\tabcellsep stakeholders, collaboration with WHO-UMC, provide for\\
\tabcellsep budgetary provisions \&administrative support to run PvPI.\end{longtable} \par
 
\caption{\label{tab_1}Table 2 :}\end{figure}
 		 		\backmatter   			 
\subsection[{Acknowledgement}]{Acknowledgement}\par
None 			  			 
\subsection[{Conflict of Interest}]{Conflict of Interest}\par
The Authors declare that there is no conflict of interest.\par
Abbreviations: WHO: World health organization, CDSCO: Central drugs standard control organization, PvPI: Pharmacovigilance programme of India, NCC: National coordinating centre, AIIMS: All India institute of medical sciences, IPC: Indian pharmacopoeia commission, PV: Pharmacovigilance, ADR: Adverse drug reaction, AMC: ADR monitoring centre, UMC: Uppsala monitoring centre.			 			  				\begin{bibitemlist}{1}
\bibitem[Najafi ()]{b7}\label{b7} 	 		‘1-2. 10. WHO Drug Information. Pharmacovigilance Programme of India. Safety of medicines: The journey travelled and the way forward’.  		 			S Najafi 		.  	 	 		\textit{Journal of Pharmacovigilance}  		2018. 2018. 6  (1)  p. .  	 	 (Importance of Pharmacovigilance and the Role of Healthcare Professionals) 
\bibitem[Routledge ()]{b8}\label{b8} 	 		‘150 years of pharmacovigilance’.  		 			P Routledge 		.  	 	 		\textit{The Lancet}  		2018. 351  (9110)  p. .  	 
\bibitem[Srivastava ()]{b3}\label{b3} 	 		\textit{A complete text book of medical pharmacology},  		 			S K Srivastava 		.  		2017. 56 p. 888.  	 	 (1 st edition) 
\bibitem[Panja et al. ()]{b19}\label{b19} 	 		‘A cross-sectional study of adverse drug reactions reporting among doctors of a private medical college in Bihar’.  		 			B Panja 		,  		 			S Bhowmick 		,  		 			V R Chowrasia 		,  		 			S Bhattacharya 		,  		 			R N Chatterjee 		,  		 			A Sen 		.  	 	 		\textit{India Indian J Pharmacol}  		2015. 47  (1)  p. .  	 
\bibitem[Nimesh and Parkash ()]{b0}\label{b0} 	 		‘A Targeted Pharmacovigilance Study on Antitubercular Drugs in the Department of Pulmonary Medicine at Tertiary Care Teaching Hospital in Rural Area’.  		 			S Nimesh 		,  		 			Prem Parkash 		,  		 			K 		.  	 	 		\textit{Int J Pharmacovigil}  		2019. 4  (1)  p. .  	 
\bibitem[Bester et al. ()]{b15}\label{b15} 	 		‘Anaesthesia for paediatric patients: Minimising the risk’.  		 			K Bester 		,  		 			H Meyer 		,  		 			M Crowther 		,  		 			Gray 		.  	 	 		\textit{S Afr Med J}  		2018. 108  (6)  p. .  	 
\bibitem[Khan et al. ()]{b12}\label{b12} 	 		‘Assessment of prescribing trend of drugs at out patient's chest ward of government tertiary care hospital situated in karachi’.  		 			M A Khan 		,  		 			S I Ali 		,  		 			S Alam 		.  	 	 		\textit{Journal of Bioequivalence \& Bioavailability}  		2018. 10  (1)  p. .  	 
\bibitem[Birungi et al. ()]{b13}\label{b13} 	 		‘Assessment of the isoniazid preventive therapy uptake and associated characteristics: a crosssectional study’.  		 			F M Birungi 		,  		 			S Graham 		,  		 			J Uwimana 		.  	 	 		\textit{Tuberculosis Research and Treatment}  		2018. p. .  	 
\bibitem[Lal et al. ()]{b22}\label{b22} 	 		‘Comparative study of the efficacy and safety of the ophylline and doxofylline in patients with bronchial asthma and chronic obstructive pulmonary disease’.  		 			D Lal 		,  		 			S Manocha 		,  		 			Ray A Vijayan 		,  		 			V K Kumar 		,  		 			R 		.  	 	 		\textit{J Basic Clin Physiol Pharmacol}  		2015. 26  (5)  p. .  	 
\bibitem[Central and Division ()]{b2}\label{b2} 	 		‘Directorate general of health services, ministry of health and family welfare’.  		 			T B Central 		,  		 			Division 		.  	 	 		\textit{TB India}  		2006. 2006. MFHW.  	 	 (RNTCP status report) 
\bibitem[West ()]{b17}\label{b17} 	 		\textit{Elixir Sulfanilamide was a breakthrough antibiotic-until it killed more than 100 people. The Atlantic},  		 			J West 		.  		2018.  	 	 (The Accidental Poison That Founded the Modern FDA) 
\bibitem[Najafi ()]{b24}\label{b24} 	 		‘Importance of Pharmacovigilance and the Role of Healthcare Professionals’.  		 			S Najafi 		.  	 	 		\textit{Journal of Pharmacovigilance}  		2018. 6  (1)  p. .  	 
\bibitem[Magazine et al. ()]{b21}\label{b21} 	 		‘Kamath A. Comparison of oral montelukast with oral zileuton in acute asthma: A randomized, double-blind, placebo-controlled study’.  		 			R Magazine 		,  		 			H A Shahul 		,  		 			B Chogtu 		.  	 	 		\textit{Lung India}  		2016. 33  (3)  p. .  	 
\bibitem[Lande et al. ()]{b23}\label{b23} 	 		‘Newer initiatives under rntcp’.  		 			H B Lande 		,  		 			S W Kamble 		,  		 			M S Pawar 		,  		 			S C Mohapatra 		.  	 	 		\textit{J Adv Res Med Sci Tech}  		2016. 3  (1)  p. .  	 
\bibitem[Pharmacovigilance & Risk Management Strategies Forum. 5 th Annual Flemming Conference]{b10}\label{b10} 	 		\textit{Pharmacovigilance \& Risk Management Strategies Forum. 5 th Annual Flemming Conference},  				 (Philadelphia, P A)  		 	 
\bibitem[Kalaiselvan et al. ()]{b14}\label{b14} 	 		‘Pharmacovigilance Programme of India: Recent developments and future perspectives’.  		 			V Kalaiselvan 		,  		 			P Thota 		,  		 			G N Singh 		.  	 	 		\textit{Indian J Pharmacol}  		2016. 48  (6)  p. .  	 
\bibitem[Singh and Kanase ()]{b18}\label{b18} 	 		\textit{Pharmacovigilance Programme of India: The Beginning, Current Status and Recent Progress},  		 			Knm Singh 		,  		 			H R Kanase 		.  		2017. 6 p. .  	 	 (Advances in Pharmacoepidemiology and Drug Safety) 
\bibitem[Parthasarathi et al. ()]{b11}\label{b11} 	 		‘Pharmacovigilance Research in India: A Five-Year Literature Review’.  		 			G Parthasarathi 		,  		 			A Harugeri 		,  		 			K Undela 		.  	 	 		\textit{Proc Indian Natn Sci Acad}  		2018. 8 p. .  	 
\bibitem[Nimesh and Ashwlayan ()]{b1}\label{b1} 	 		‘Pharmacovigilance: An Overview’.  		 			S Nimesh 		,  		 			V D Ashwlayan 		.  	 	 		\textit{International Journal of Pharmacovigilance}  		2018. 3  (1)  p. .  	 
\bibitem[Mohamed and Elnagar ()]{b5}\label{b5} 	 		‘Prevalence and Extent of Adverse Drug Reactions in Sudanese Patients in Highly Active Antiretroviral Therapy Regimens’.  		 			B Mohamed 		,  		 			I Elnagar 		.  	 	 		\textit{Int J Pharmacovigilance}  		2017. 2  (2)  p. .  	 
\bibitem[PvPI reaches out to rural masses Newsletter Pharmacovigilance Programme of India ()]{b9}\label{b9} 	 		‘PvPI reaches out to rural masses’.  	 	 		\textit{Newsletter Pharmacovigilance Programme of India}  		2017.  	 
\bibitem[Krishnamurti ()]{b16}\label{b16} 	 		‘Reprieves before rejection: chloroform for anesthesia’.  		 			C Krishnamurti 		.  	 	 		\textit{International Journal of Scientific Research}  		2018. 7  (3)  p. .  	 
\bibitem[Zhu et al. ()]{b6}\label{b6} 	 		‘Selective upper airway stimulation in older patients’.  		 			Z Zhu 		,  		 			B Hofauer 		,  		 			M Wirth 		,  		 			Katrin Hasselbacher 		,  		 			Helmut Frohnhofen 		,  		 			Clemens Heiser 		.  	 	 		\textit{Respiratory medicine}  		2018. 140 p. .  	 
\bibitem[Ndagije et al. ()]{b20}\label{b20} 	 		‘Targeted spontaneous reporting of suspected renal toxicity in patients undergoing highly active anti-retroviral therapy in two public health facilities in Uganda’.  		 			H Ndagije 		,  		 			V Nambasa 		,  		 			E Namagala 		,  		 			H Nassali 		,  		 			D Kajungu 		,  		 			G Sematiko 		.  	 	 		\textit{Drug Saf}  		2015. 38  (4)  p. .  	 
\bibitem[The Bio-Medical Waste Management (Amendment) Rules ()]{b4}\label{b4} 	 		\textit{The Bio-Medical Waste Management (Amendment) Rules},  		2018.  	 
\end{bibitemlist}
 			 		 	 
\end{document}
